Literature DB >> 22252846

Reversible acute encephalopathy with mutism, induced by calcineurin inhibitors after renal transplantation.

Katia Toledo Perdomo1, María-Dolores Navarro Cabello, María-José Pérez Sáez, Manuel José Ramos Pérez, Maria Luisa Agüera Morales, Pedro Aljama García.   

Abstract

The incidence of neurotoxicity from calcineurin inhibitors varies by the organ transplanted. Akinetic mutism is characterized by the inability to perform voluntary movements and express language, without alterations in mental status. This process has been reported in neurotoxicity due to high serum levels of calcineurin inhibitors, but in rare cases, it presents as a form of tacrolimus toxicity after renal transplantation, despite normal serum levels. We report a clinical case of a renal transplant patient in whom reversible acute encephalopathy and akinetic mutism developed. Brain lesions appeared on magnetic resonance imaging, and the condition resolved after the drug was withdrawn.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22252846     DOI: 10.5301/jn.5000080

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  3 in total

1.  Late onset of progressive speech impairment due to tacrolimus-associated leukoencephalopathy after kidney transplantation.

Authors:  Kazushige Sato; Yuichi Miura; Yuhji Marui; Kiho Tanaka; Shinji Tomikawa
Journal:  Int Urol Nephrol       Date:  2015-06-14       Impact factor: 2.370

2.  The investigation of correlation between Iminoral concentration and neurotoxic levels after kidney transplantation.

Authors:  Zahra Tolou-Ghamari; Mojgan Mortazavi; Abbas-Ali Palizban; Mohammad-Reza Najafi
Journal:  Adv Biomed Res       Date:  2015-02-23

3.  An Elastomeric Polymer Matrix, PEUU-Tac, Delivers Bioactive Tacrolimus Transdurally to the CNS in Rat.

Authors:  Yolandi van der Merwe; Anne E Faust; Ian Conner; Xinzhu Gu; Firuz Feturi; Wenchen Zhao; Bianca Leonard; Souvik Roy; Vijay S Gorantla; Raman Venkataramanan; Kia M Washington; William R Wagner; Michael B Steketee
Journal:  EBioMedicine       Date:  2017-11-24       Impact factor: 8.143

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.